Neurocrine Biosciences (NBIX) EPS (Diluted) (2010 - 2026)
Neurocrine Biosciences (NBIX) reported EPS (Diluted) of $1.39 for Q2 2026, up 30.2% from $1.06 a year earlier but down 27.6% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EPS (Diluted) (2010 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Neurocrine Biosciences' EPS (Diluted) came in at $6.77, up 96.3% year-over-year; for FY2025, it came in at $4.67, up 41.9% from FY2024.
- EPS (Diluted) has increased for four consecutive years, with a five-year compound annual growth rate of 2.3% (FY2020 to FY2025).
- By year, EPS (Diluted) came in at $3.29 in FY2024 (+33.1%), $2.47 in FY2023 (+58.3%), $1.56 in FY2022 (+70.7%) and $0.92 in FY2021 (-78.0%).
- Five-year quarterly EPS (Diluted) spans a low of -$0.79 in Q1 2023 and a high of $2.04 in Q3 2025.
- Year over year, EPS (Diluted) gained in five of the last seven quarters, with growth averaging 21.9%.
- The high point for year-over-year EPS (Diluted) in five years was Q3 2022 (growth of 200.4%); the low point was Q1 2025 (a decline of 81.6%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $1.91 (Q1 2026), $1.50 (Q4 2025) and $2.04 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 2.27 |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 2.04 |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -0.54 |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 1.67 |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 1.85 |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 4.37 |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -8.44 |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -0.04 |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 4.31 |
| 10 | Neurocrine Biosciences | 14.41 Bn | 10.11 Bn | 935.80 Mn | 1.39 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.39 |
| Mar 31, 2026 | 1.91 |
| Dec 31, 2025 | 1.50 |
| Sep 30, 2025 | 2.04 |
| Jun 30, 2025 | 1.06 |
| Mar 31, 2025 | 0.08 |
| Dec 31, 2024 | 0.99 |
| Sep 30, 2024 | 1.24 |
| Jun 30, 2024 | 0.63 |
| Mar 31, 2024 | 0.42 |
| Dec 31, 2023 | 1.46 |
| Sep 30, 2023 | 0.82 |
| Jun 30, 2023 | 0.95 |
| Mar 31, 2023 | -0.79 |
| Dec 31, 2022 | 0.90 |
| Sep 30, 2022 | 0.69 |
| Jun 30, 2022 | -0.18 |
| Mar 31, 2022 | 0.14 |
| Dec 31, 2021 | -0.07 |
| Sep 30, 2021 | 0.23 |
API Access
Neurocrine Biosciences EPS (Diluted) API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=eps-diluted&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "eps-diluted", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=eps-diluted&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();